Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference

Cutis

Volumn 70, Issue 6, 2002, Pages 327-332

  Housman, Tamara Salam ^a   Mellen, Beverly G ^a   Rapp, Stephen R ^b   Fleischer Jr , Alan B ^a   Feldman, Steven R ^a,b  

^a Department of Dermatology ^*  (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; DRUG VEHICLE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; PATIENT ATTITUDE; PSORIASIS; QUALITY OF LIFE; SKIN ABSORPTION; SOLUTION AND SOLUBILITY; TOPICAL DRUG ADMINISTRATION; VEHICLES;

ADMINISTRATION, TOPICAL; ADULT; AGED; DERMATOLOGIC AGENTS; FEMALE; FOCUS GROUPS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PSORIASIS; QUALITY OF LIFE; SKIN ABSORPTION; SOLUTIONS; VEHICLES;

EID: 0036886338     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 pt 1):401-407.
2. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? what constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43(2 pt 1):281-285.
3. Trozak DJ. Topical corticosteroid therapy in psoriasis vulgaris. Cutis. 1990;46:341-350.
4. Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2:525-537.
5. Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39(2 pt 3):S67-S73.
6. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197:31-36.
7. Dunlap FE, Mills OH, Tuley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol. 1998;139:17-22.
8. Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. J Eur Acad Dermatol Venereol. 2000;14:153-158.
9. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25(6 pt 2):1166-1169.
10. Reinberg A, Koulbanis C, Soudant E, et al. Day-night differences in effects of cosmetic treatments on facial skin: effects on facial skin appearance. Chronobiol Int. 1990;7:69-79.
11. Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol. 1987;123:1312-1314.
12. Berndt U, Wigger-Alberti W, Gabard B, et al. Efficacy of a barrier cream and its vehicle as protective measures against occupational irritant contact dermatitis. Contact Dermatitis. 2000;42:77-80.
13. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40(6 pt 1):961-965.